# IL3 CAR-T Cell Therapy for Patients With CD123 Positive Relapsed and/or Refractory Acute Myeloid Leukemia

> **NCT04599543** · EARLY_PHASE1 · NOT_YET_RECRUITING · sponsor: **Zhejiang University** · enrollment: 36 (estimated)

## Conditions studied

- Acute Myeloid Leukemia

## Interventions

- **DRUG:** IL3 CAR T-cells

## Key facts

- **NCT ID:** NCT04599543
- **Lead sponsor:** Zhejiang University
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2020-11-15
- **Primary completion:** 2023-11-15
- **Final completion:** 2026-11-15
- **Target enrollment:** 36 (ESTIMATED)
- **Last updated:** 2020-10-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04599543

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04599543, "IL3 CAR-T Cell Therapy for Patients With CD123 Positive Relapsed and/or Refractory Acute Myeloid Leukemia". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT04599543. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*